Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

TAK vs HLN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TAK Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 6–4 Matrix Metrics)

TAK Overall Winner 6-Pillar Tally: TAK 4 – 1 HLN (1 Tie) Matrix Metrics: TAK 6 – 4 HLN

As of Nov 16, 2026, Takeda Pharmaceutical Company Limited (TAK) is the stronger overall head-to-head candidate over Haleon plc (HLN) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). TAK carries a Unified Composite Score of 47.7/100 (HOLD) at $21.61 (12.7x Forward P/E, 16.6% operating margin), whereas HLN carries 44.6/100 (HOLD) at $9.21 (15.2x Forward P/E, 23.5% operating margin).

  • Technical & Structure Timing Caution: TAK trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 73.1); meanwhile HLN is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 48.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About TAK vs HLN
TAK NYSE Head-to-Head Winner
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Pharmaceutical Preparations
$21.61
+0.86% 1D
Market Cap $67.5B
TTM Revenue $25.7B
Forward P/E 12.7x
Beta / 30D Vol -0.02β · 22% Vol
Unified Composite Score
47.7 / 100 HOLD
Tech 42.0 Fund 43.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (5.9% over 20 days), RSI 73
RSI-14: 73.1 · SMA20: $20.72 · SMA50: $19.46
HLN NYSE
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
Perfumes, Cosmetics & Other Toilet Preparations
$9.21
+0.38% 1D
Market Cap $40.3B
TTM Revenue $11.2B
Forward P/E 15.2x
Beta / 30D Vol -0.02β · 56% Vol
Unified Composite Score
44.6 / 100 HOLD
Tech 63.0 Fund 55.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -2.1%) with fading momentum, RSI 48
RSI-14: 48.3 · SMA20: $9.40 · SMA50: $9.33

6-Pillar Scorecard Institutional Category Breakdown (TAK 4 – 1 HLN)

Columns: Metric · TAK · HLN
1. Valuation Multiples TAK
Forward P/E 12.7x 15.2x
Trailing P/E N/M 18.8x
PEG Ratio 0.47x 2.08x
EV / Revenue 2.6x 3.6x
2. Growth & Scale TAK
Revenue Growth (YoY) +6.7% +2.2%
Earnings Growth (YoY) -9.8% -4.5%
TTM Revenue (USD) $25.7B $11.2B
Market Cap $67.5B $40.3B
3. Profitability & Quality HLN
Gross Margin 64.8% 65.6%
Operating Margin 16.6% 23.5%
Net Profit Margin 0.9% 14.5%
Return on Equity (ROE) 0.6% 10.1%
4. Balance Sheet & Cash Flow TAK
Cash Generation (TTM) $7.48B EBITDA $2.85B EBITDA
Cash Flow Margin 29.1% EBITDA Mgn 25.5% EBITDA Mgn
Net Cash / Leverage $14.68 Book/Sh · 0.6% ROE $4.94 Book/Sh · 10.1% ROE
Dividend Yield 2.92% 2.18%
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 22.4% (5th %ile) 20.3% (6th %ile)
Put/Call OI Skew Thin ADR Chain Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Distribution
6. R&D & Supply-Chain Moat TAK
OpEx & R&D Intensity 48.2% of Rev ($12.4B) 42.1% of Rev ($4.69B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Scale & Operating Efficiency Moat
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: TAK (6) vs HLN (4)
Institutional Metric TAK HLN Criterion Row Edge
Market Capitalization
Scale
$67.5B $40.3B Larger Scale TAK
Trailing P/E Ratio
Valuation
N/M 18.8x Lower Multiple HLN
Forward P/E Ratio
Valuation
12.7x 15.2x Lower Multiple TAK
Revenue Growth (YoY)
Growth
+6.7% +2.2% Higher Growth TAK
Operating Margin (TTM)
Profitability
16.6% 23.5% Higher Margin HLN
Net Profit Margin
Profitability
0.9% 14.5% Higher Margin HLN
Return on Equity (ROE)
Capital Efficiency
0.6% 10.1% Higher ROE HLN
52-Week Range Position
Momentum
97% ($14–$22) 28% ($8–$11) Stronger Trend TAK
Beta / 30D Volatility
Risk Regime
-0.02β · 22% Vol -0.02β · 56% Vol Lower Realized Risk TAK
Unified Institutional Score
Composite Signal
47.7 / 100 (HOLD) 44.6 / 100 (HOLD) Higher Composite TAK
Trailing 12M Revenue (USD)
Operating Scale
$25.7B $11.2B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
64.8% 65.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.47x PEG · 2.6x EV/Rev 2.08x PEG · 3.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$7.48B EBITDA ($14.68 Book/Sh · 0.6% ROE) $2.85B EBITDA ($4.94 Book/Sh · 10.1% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon TAK +19.02 pp
TAK: +9.89% · HLN: -9.13%
3M Horizon TAK +25.05 pp
TAK: +19.75% · HLN: -5.3%
6M Horizon TAK +30.07 pp
TAK: +30.45% · HLN: +0.38%
1Y Horizon TAK +58.81 pp
TAK: +51.79% · HLN: -7.02%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TAK vs HLN. Trailing 12-month operating profitability (TAK 16.6% vs HLN 23.5%) and valuation multiples (TAK 12.7x vs HLN 15.2x Forward P/E) are benchmarked directly in Pillar 4 below.

TAK ADR TTM Benchmark FX-Normalized USD
TTM Revenue$25.7B
Gross Margin64.8%
Op. Margin16.6%
ROE / Fwd P/E0.6% · 12.7x
HLN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$11.2B
Gross Margin65.6%
Op. Margin23.5%
ROE / Fwd P/E10.1% · 15.2x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
TAK UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 22.4%
IV Percentile 5th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TAK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
HLN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 20.3%
IV Percentile 6th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact HLN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
TAK Moat Profile Scale & Operating Efficiency Moat
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $67.5B market capitalization and 16.6% operating margin.
OpEx & R&D Reinvestment 48.2% of Rev ($12.4B)
90D Engineering Disclosures 0 Published
HLN Moat Profile Scale & Operating Efficiency Moat
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $40.3B market capitalization and 23.5% operating margin.
OpEx & R&D Reinvestment 42.1% of Rev ($4.69B)
90D Engineering Disclosures 0 Published

Investor FAQ TAK vs HLN Key Questions & Quantitative Answers

As of Nov 16, 2026, Takeda Pharmaceutical Company Limited (TAK) is the stronger overall head-to-head candidate over Haleon plc (HLN) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). TAK carries a Unified Composite Score of 47.7/100 (HOLD) at $21.61 (12.7x Forward P/E, 16.6% operating margin), whereas HLN carries 44.6/100 (HOLD) at $9.21 (15.2x Forward P/E, 23.5% operating margin). Technical & Structure Timing Caution: TAK trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 73.1); meanwhile HLN is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 48.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

TAK leads the Growth & Scale pillar: TAK posts +6.7% YoY revenue growth and -9.8% YoY earnings growth on $25.7B TTM revenue (64.8% gross margin, 16.6% operating margin), compared with HLN at +2.2% YoY revenue growth and -4.5% YoY earnings growth on $11.2B TTM revenue (65.6% gross margin, 23.5% operating margin). On trailing 12-month operating scale, TAK generates $25.7B in USD-normalized revenue versus $11.2B for HLN. In operating R&D and SG&A reinvestment, TAK deploys 48.2% of Rev ($12.4B) (0 90-day corporate R&D disclosures) versus 42.1% of Rev ($4.69B) (0 disclosures) for HLN.

TAK screens cheaper on headline valuation multiples. TAK trades at 12.7x Forward P/E, N/M Trailing P/E, 0.47x PEG, and 2.6x EV/Revenue (29.1% EBITDA margin), whereas HLN trades at 15.2x Forward P/E, 18.8x Trailing P/E, 2.08x PEG, and 3.6x EV/Revenue (25.5% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TAK (0.6% ROE) versus HLN (10.1% ROE) capital efficiency.

In options market volatility and institutional positioning, TAK carries 22.4% implied volatility (5th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.02β · 22% Vol realized risk). By comparison, HLN carries 20.3% implied volatility (6th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.02β · 56% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Research Suite

Haleon plc American Depositary Shares (Each representing two Ordinary Shares) (HLN) Research Suite

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.